openPR Logo
Press release

Oral Mucositis Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years

06-08-2017 06:01 PM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

Oral Mucositis Therapeutics Pipeline to Witness Many

The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates, of which one drug candidate is in Phase III stage of development, while seven drug candidates are in Phase II stage, four drug candidates are in Phase I stage, five drug candidates are in Pre-Clinical stage and one drug candidate is in the Discovery stage. Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.

Access Report Overview: www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis

Insights on pipeline segments

As per the findings of the research, around 39.0% drug candidates of oral mucositis pipeline are being developed to be administered by topical route, 17.0% are being developed to be administered by oral route, 17.0% are being developed to be administered by intravenous route and 5.0% by subcutaneous route. Route of administration of around 22.0% drug candidates of oral mucositis pipeline is not disclosed.

Explore Report Sample at: www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis/report-sample

Various Companies in the pipeline received Designations from theUSFDA for the development of Oral Mucositis Therapeutics Pipeline

The research also found that various companies received designations from the USFDA for the development of the drugs in the oral mucositis therapeutics pipeline. In November 2016, USFDA granted Fast Track designation to AG013 for the treatment of oral mucositis. In November 2015, USFDA granted Fast Track designation to Brilacidin for the treatment of oral mucositis.

Many companies are involved in the development of drugs for the oral mucositis therapeutics pipeline, with their products in different phases. Daewoong Pharmaceutical Co., Ltd. has its drug candidates in the Phase III stage of development. Cellceutix Corporation, Onxeo S.A. and Novartis AG have their drug candidates in the Phase II stage of development. Galera Therapeutics, Inc. has two drug candidates each in Phase II and Phase I stage of development. Oragenics, Inc. has one drug candidate in Discovery stage of development.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc., Onxeo S.A., Novartis AG, TFS Corporation, Izun Pharmaceuticals Corp., Oragenics, Inc., Wellstat Therapeutics Corporation, Otsuka Holdings Co., Ltd. and Galera Therapeutics, Inc.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oral Mucositis Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years here

News-ID: 570840 • Views:

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for Phase

PanAfGeo: The Second Phase Begins!
The PanAfGeo community is pleased to announce the launching of the PanAfGeo second phase (PanAfGeo-2), which will continue to build on the first phase project’s achievements over the next three years. PanAfGeo, an EU co-funded initiative that began in 2016, contributed to the transfer of knowledge between European and African Geological Surveys. PanAfGeo also ensured the institutional strengthening of many African national administrations in charge of geology and mining. With the backing
COVID-19 - Pipeline Analysis 2020 for Global Market | Emphasis on Products cover …
COVID-19 (also known as Anderson COVID-19)?is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other
Power Metering Market Information by type (smart, digital, analog), by phase (si …
Power Metering Market Information by type (smart, digital, analog), by phase (single phase, three phase) by application (residential, commercial and industrial) and Region - Forecast to 2022 The report for Global Power Metering Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and
HIV Vaccines Market Perceive Aggrandized Growth at a CAGR of 11.48% Till 2023 | …
HIV Vaccines Market Report Added on MarketResearchFuture.com with Overall Analysis. Key developments and Strategies Cover in this Report. The Market for Expected to Grow Globally Over the CAGR of 5 % During the Period 2018 to 2027 from USD 2,702.3 Billion in 2027. HIV Vaccines Market - Segmentation The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region. Antibiotics have been segmented into dicloxacillin,
2026 Global Pharmacovigilance Market Growth Analysis by Clinical Trials Like Pre …
Global Pharmacovigilance Market 2018 report includes extensive Market analysis and industry landscape along with SWOT analysis and PESTEL analysis of the important vendors. The analysis is conducted with a blend of secondary and primary advice for inputs from participants in the industry. Pharmacovigilance industry report covers the prospects of Women’S Health P oducts in the forecast period of 2018-2026 and the scenario. Growing prevalence of adverse reactions caused by drugs, has
MAAT Inaugurates Versatile Phase Shifter
Company announces release of a digital recreation of Roger Schult’s analog hardware MAAT Incorporated, a manufacturer of exceptional performance professional audio solutions, today announced the release of RSPhaseShifter version 1.0, a digital implementation of the Roger Schult/German Audio Lab’s Phase Shifter 500 Series W2324 hardware. The cross–platform plug–in creates a high quality, phase shifted version of a monaural or stereo input. Available in formats for all major DAWs (Digital Audio Workstations), RSPhaseShifter